SCHEMBL29035153

SCHEMBL29035153

CC(C)(C)OC(=O)NCc1cc(C(=N)NO)c(F)s1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 1/20 0.37
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
CACNA1H O95180 1/20 0.34
CACNA1B Q00975 1/20 0.34
CACNA1C Q13936 1/20 0.34
HDAC1 Q13547 4/20 0.34
HDAC6 Q9UBN7 4/20 0.34
GLS O94925 2/20 0.34
HDAC3 O15379 2/20 0.34
HDAC10 Q969S8 2/20 0.34
GRM2 Q14416 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
NAMPT P43490 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29523802 0.90 KDM4A (0.37) KDM4ACA12CA1CA2CA9
SCHEMBL29523586 0.87 CA1 (0.35) KDM4ACA12CA1CA2CA9
SCHEMBL29523614 0.86 CA12 (0.38) KDM4ACA12CA1CA2CA9
SCHEMBL25363707 0.83 ATM (0.33) KDM4ACA12CA1GLSGAA
SCHEMBL25365021 0.80
SCHEMBL29035181 0.78 TRPA1 (0.41) KDM4ACA12CA1CA2CA9
Hydrochloric Acid SCHEMBL29523585 0.76 APLNR (0.32) CA12CA1CA2CA9
SCHEMBL30739040 0.76 EPHX2 (0.46) KDM4AHDAC1HDAC6GLSHDAC10
SCHEMBL29035340 0.75 KDM4A (0.41) KDM4ACACNA1HCACNA1BCACNA1CHDAC1
SCHEMBL18300596 0.73 KDM4A (0.41) KDM4ACA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed
WO-2022066774-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2022-03-31 WO disclosed